Accepted Manuscript

Preeclampsia in High Risk Women is Characterized by Risk Group-Specific Abnormalities in Serum Biomarkers

Torri D. Metz, MD, MS Amanda A. Allshouse, MS Anna G. Euser, MD, PhD Kent D. Heyborne, MD

PII: S0002-9378(14)00387-1

DOI: 10.1016/j.ajog.2014.04.027

Reference: YMOB 9796

To appear in: American Journal of Obstetrics and Gynecology

Received Date: 15 January 2014
Revised Date: 19 March 2014
Accepted Date: 17 April 2014

Please cite this article as: Metz TD, Allshouse AA, Euser AG, Heyborne KD, Preeclampsia in High Risk Women is Characterized by Risk Group-Specific Abnormalities in Serum Biomarkers, *American Journal of Obstetrics and Gynecology* (2014), doi: 10.1016/j.ajog.2014.04.027.

This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.



Preeclampsia in High Risk Women is Characterized by Risk Group-Specific Abnormalities in Serum Biomarkers

Torri D. METZ, MD, MS^{1,2}, Ms. Amanda A. Allshouse, MS³, Anna G. Euser, MD, PhD¹, and Kent D. Heyborne, MD^{1,2}

¹University of Colorado Denver, Department of Obstetrics and Gynecology, Aurora, CO

²Denver Health Medical Center, Department of Obstetrics and Gynecology, Denver, CO

³University of Colorado School of Public Health, Aurora, CO

Not previously presented.

Address for correspondence: Torri Metz, M.D., Department of Obstetrics and Gynecology, Denver Health Medical Center, 777 Bannock St, Denver, CO 80204 USA, phone: 303-602-9727, fax: 303-602-9734, email: torri.metz@dhha.org. Reprints will not be available.

Abstract word count: 249, Text word count: 2181

None of the authors have a conflict of interest. The authors appreciate the assistance of the National Institute of Child Health and Human Development (NICHD) and the Maternal-Fetal Medicine Units Network in making the database from the MFMU High-Risk Aspirin trial available for secondary analysis. The contents of this report represent the views of the authors and do not represent the views of the *Eunice Kennedy Shriver* NICHD Maternal-Fetal Medicine Units Network or the National Institutes of Health.

Download English Version:

https://daneshyari.com/en/article/6145506

Download Persian Version:

https://daneshyari.com/article/6145506

<u>Daneshyari.com</u>